State Street’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.33M | Sell |
331,772
-665,333
| -67% | -$2.66M | ﹤0.01% | 3427 |
|
|
2025
Q1 | $907K | Sell |
997,105
-10,350
| -1% | -$9.42K | ﹤0.01% | 3451 |
|
|
2024
Q4 | $2.79M | Sell |
1,007,455
-42,965
| -4% | -$119K | ﹤0.01% | 3207 |
|
|
2024
Q3 | $5.49M | Buy |
1,050,420
+50,386
| +5% | +$264K | ﹤0.01% | 2922 |
|
|
2024
Q2 | $4.46M | Buy |
1,000,034
+119,395
| +14% | +$533K | ﹤0.01% | 2977 |
|
|
2024
Q1 | $6.75M | Buy |
880,639
+134,106
| +18% | +$1.03M | ﹤0.01% | 2798 |
|
|
2023
Q4 | $3.18M | Buy |
746,533
+118,186
| +19% | +$503K | ﹤0.01% | 3146 |
|
|
2023
Q3 | $2.64M | Buy |
628,347
+67,505
| +12% | +$284K | ﹤0.01% | 3208 |
|
|
2023
Q2 | $3.12M | Buy |
560,842
+462,787
| +472% | +$2.58M | ﹤0.01% | 3214 |
|
|
2023
Q1 | $562K | Buy |
98,055
+21,700
| +28% | +$124K | ﹤0.01% | 3703 |
|
|
2022
Q4 | $80.2K | Hold |
76,355
| – | – | ﹤0.01% | 4434 |
|
|
2022
Q3 | $205K | Buy |
76,355
+27,300
| +56% | +$73.3K | ﹤0.01% | 4132 |
|
|
2022
Q2 | $234K | Sell |
49,055
-139,950
| -74% | -$668K | ﹤0.01% | 4127 |
|
|
2022
Q1 | $773K | Buy |
189,005
+1,903
| +1% | +$7.78K | ﹤0.01% | 3890 |
|
|
2021
Q4 | $1.28M | Sell |
187,102
-1,165
| -0.6% | -$7.95K | ﹤0.01% | 3756 |
|
|
2021
Q3 | $2.18M | Buy |
188,267
+18,378
| +11% | +$213K | ﹤0.01% | 3588 |
|
|
2021
Q2 | $2.9M | Buy |
169,889
+37,670
| +28% | +$642K | ﹤0.01% | 3478 |
|
|
2021
Q1 | $2.62M | Buy |
132,219
+14,640
| +12% | +$290K | ﹤0.01% | 3324 |
|
|
2020
Q4 | $2.43M | Buy |
117,579
+46,994
| +67% | +$970K | ﹤0.01% | 3285 |
|
|
2020
Q3 | $1.86M | Buy |
+70,585
| New | +$1.86M | ﹤0.01% | 3230 |
|